Your Health, We Care
Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with brigatinib.
In ALTA 1L, hypertension was reported in 32% of patients receiving brigatinib; Grade 3 hypertension occurred in 13% of patients.
In ALTA 1L, heart rates less than 50 beats per minute (bpm) occurred in 8.1% of patients receiving brigatinib. Grade 3 bradycardia occurred in 1 patient (0.7%).
In ALTA 1L, Grade 1 or 2 adverse reactions leading to visual disturbance including blurred vision, photophobia, photopsia, and reduced visual acuity were reported in 7.4% of patients receiving brigatinib.
In ALTA 1L, creatine phosphokinase (CPK) elevation occurred in 81% of patients who received brigatinib. The incidence of Grade 3 or 4 CPK elevation was 24%. Dose reduction for CPK elevation occurred in 15% of patients.
In ALTA 1L, amylase elevation occurred in 52% of patients and Grade 3 or 4 amylase elevation occurred in 6.8% of patients. Lipase elevations occurred in 59% of patients and Grade 3 or 4 lipase elevation occurred in 17% of patients.
In ALTA 1L, aspartate aminotransferase (AST) elevations occurred in 72% of patients and Grade 3 or 4 AST elevations occurred in 4.5% of patients. Alanine aminotransferase (ALT) elevations occurred in 52% of patients and Grade 3 or 4 ALT elevations occurred in 5.2% of patients. One patient (0.7%) had a serious adverse reaction of hepatocellular injury.
from FDA，2022.02
